Literature DB >> 35474542

Extracranial medulloepithelioma: a review of the literature.

David Bailey1, Christine Mau2, Christina Toepke3, Elizabeth Finch3, Elias Rizk2.   

Abstract

PURPOSE: Medulloepithelioma is a rare, malignant tumor that typically arises in the periventricular region of the cerebral hemispheres or the ciliary body of the eye. Even rarer still is the extracranial manifestation of medulloepithelioma with only 12 cases reported to date. Our purpose is to report a case of an intradural, extra-medullary medulloepithelioma and review the limited literature about diagnosis and treatment of this extremely rare pathology.
METHODS: PubMed was queried using search terms "peripheral medulloepithelioma" and "pre-sacral medulloepithelioma." Medulloepitheliomas which were intraocular or occurred in reproductive organs were excluded. Patients' age, sex, the symptomatic period prior to diagnosis, primary tumor site, stage, treatment regimen, pathologic description, and survival outcomes were collected.
RESULTS: We present a case of extracranial medulloepithelioma in an 8-year-old male. Morphology of the neoplasm was representative of medulloepithelioma but there was no amplification of C19MC. Additionally, the neoplasm stained positive for CD99. Twelve other cases of extracranial medulloepithelioma were found in literature review.
CONCLUSIONS: The rarity of extracranial medulloepithelioma makes for a challenging diagnosis. Designing an optimal treatment strategy is difficult because of a scarcity of cases and wide variety in locations and treatments. Our case provides an example of treatment including resection, intense induction chemotherapy, consolidation with high-dose chemotherapy and stem cell rescue, craniospinal proton radiation therapy, and metronomic chemotherapy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Embryonal neoplasm; Extracranial medulloepithelioma; Rare tumors; Spine tumors

Mesh:

Year:  2022        PMID: 35474542     DOI: 10.1007/s00381-022-05525-4

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.532


  15 in total

Review 1.  Intraocular medulloepithelioma.

Authors:  Timothy Saunders; Curtis E Margo
Journal:  Arch Pathol Lab Med       Date:  2012-02       Impact factor: 5.534

2.  Successful therapy in a child with a congenital peripheral medulloepithelioma and disruption of hindquarter development.

Authors:  C S Bruggers; C T Welsh; R S Boyer; J L Byrne; T J Pysher
Journal:  J Pediatr Hematol Oncol       Date:  1999 Mar-Apr       Impact factor: 1.289

3.  Sellar and suprasellar medulloepithelioma.

Authors:  L M Pang; D J Roebuck; H K Ng; Y L Chan
Journal:  Pediatr Radiol       Date:  2001-08

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.

Authors:  Patrick Van Winkle; Anne Angiolillo; Mark Krailo; Ying-Kuen Cheung; Barry Anderson; Virginia Davenport; Gregory Reaman; Mitchell S Cairo
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167

6.  Medulloepithelioma: Two unusual locations.

Authors:  Hidehiro Takei; Luisa Florez; Krzysztof Moroz; Meenakshi B Bhattacharjee
Journal:  Pathol Int       Date:  2007-02       Impact factor: 2.534

7.  Ectopic intrapelvic medulloepithelioma: case report.

Authors:  D Figarella-Branger; D Gambarelli; M Perez-Castillo; J C Gentet; F Grisoli; J F Pellissier
Journal:  Neuropathol Appl Neurobiol       Date:  1992-08       Impact factor: 8.090

Review 8.  Primitive neuroectodermal tumors of the central nervous system.

Authors:  L E Becker; D Hinton
Journal:  Hum Pathol       Date:  1983-06       Impact factor: 3.466

9.  A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.

Authors:  Nathan J Robison; Federico Campigotto; Susan N Chi; Peter E Manley; Christopher D Turner; Mary Ann Zimmerman; Christine A Chordas; Annette M Werger; Jeffrey C Allen; Stewart Goldman; Joshua B Rubin; Michael S Isakoff; Wilbur J Pan; Ziad A Khatib; Melanie A Comito; Anne E Bendel; Jay B Pietrantonio; Laura Kondrat; Shannon M Hubbs; Donna S Neuberg; Mark W Kieran
Journal:  Pediatr Blood Cancer       Date:  2013-10-04       Impact factor: 3.167

10.  Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity.

Authors:  Andrey Korshunov; Dominik Sturm; Marina Ryzhova; Volker Hovestadt; Marco Gessi; David T W Jones; Marc Remke; Paul Northcott; Arie Perry; Daniel Picard; Marc Rosenblum; Manila Antonelli; Eleonora Aronica; Ulrich Schüller; Martin Hasselblatt; Adelheid Woehrer; Olga Zheludkova; Ella Kumirova; Stephanie Puget; Michael D Taylor; Felice Giangaspero; V Peter Collins; Andreas von Deimling; Peter Lichter; Annie Huang; Torsten Pietsch; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2013-12-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.